Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroglycerin sublingual powder for intermittent claudication in peripheral arterial occlusive disease
2016-004460-19Phase 2Completed
- Sponsor
- Pohl-Boskamp
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral artery occlusion (PAD) and intermittent claudication (IC) comparing Nitroglycerin sublingual powder with Placebo (2 arms). Primary endpoints: Change in initial claudication distance at end of treatment, Change in absolute claudication distance at end of treatment and 1 more. Started Dec 2016; status: completed.
02
Drugs
nitroglycerin
03
Conditions
peripheral artery occlusion (PAD)intermittent claudication (IC)
Beyond the preview
Go deeper on 2016-004460-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004460-19.